Ernexa Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

ERNA$2.05+9.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

	Three months ended June 30,		Six months ended June 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$2,792	$1,136	$4,707	$2,445
General and administrative	1,312	1,365	2,943	2,786
Impairment of goodwill	-	-	2,044	-
Total operating expenses	4,104	2,501	9,694	5,231
Loss from operations	(4,104)	(2,501)	(9,694)	(5,231)
Other income (expense), net:
Forward sales contract expense	-	(512)	-	(5,847)
Change in fair value of warrant liabilities	-	-	-	1
Interest income (expense), net	55	-	99	5
Gain on extinguishment of contingent liability	41	-	41	-
Other expense, net	(1)	(123)	(1)	(258)
Total other income (expense), net	95	(635)	139	(6,099)
Loss before income taxes	(4,009)	(3,136)	(9,555)	(11,330)
Benefit (provision) for income taxes	-	(3)	40	(11)
Net loss	(4,009)	(3,139)	(9,515)	(11,341)
Series A preferred stock dividend	(8)	(8)	(8)	(8)
Net loss attributable to common stockholders	$(4,017)	$(3,147)	$(9,523)	$(11,349)
Net loss per common share - basic and diluted	$(3.40)	$(15.19)	$(9.63)	$(65.22)
Weighted average shares outstanding - basic and diluted	1,183	207	989	174

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.